Safety of Remifentanil Infusion
Information source: Diskapi Teaching and Research Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Urinary Tract Problem
Intervention: remifentanil (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Diskapi Teaching and Research Hospital Official(s) and/or principal investigator(s): Jülide Ergil, MD, Study Chair, Affiliation: Ministry of Health Dıskapi Yildirim Beyazit Training and Research Hospital, Anesthesiology 1. Alp Alptekin, MD, Study Chair, Affiliation: Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital, Anesthesiology 1 Nihan Aktürk, MD, Study Chair, Affiliation: Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital , Anesthesiology 1 Haluk Gümüs, MD, Study Chair, Affiliation: Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital, Anesthesiology 1
Summary
The effect of maintenance remifentanil infusion with target controlled infusion during
laryngeal mask airway removal on hemodynamic parameters and emergence quality is going to be
investigated.
Clinical Details
Official title: The Effects of Maintenance a Remifentanil Infusion on the Hemodynamic Variables and Recovery Quality
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Smooth cLMA Removal Condition (Score 1)
Detailed description:
In all patients (control group and remifentanil group induction of anesthesia will be
achieved with desflurane and remifentanil. Anesthesia will be maintained with remifentanil
(1-4 ng/mL) by TCI target controlled infusion, and desflurane . Throughout the surgery
hemodynamic parameters are going to be recorded. As soon as the surgery has been finished,
in control group remifentanil infusion and desflurane inhalation is going to be stopped. In
remifentanil group,desflurane inhalation is going to be stopped and remifentanil infusion
will be maintained until the removal of LMA. During the emergence period the time of eye
opening, hemodynamic parameters and emergence quality (score 1-2)are going to be recorded.
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- ASA I-II status
- aged 18-60 years old
- presenting for ureterorenoscopy
Exclusion Criteria:
- history of hypertension
- asthma and chronic obstructive lung disease
- recent respiratory tract infections
Locations and Contacts
Ministry of Health Diskapi Yildirim Beyazit Research and Training Hospital departement of 1. Anesthesiology, Ankara 06110, Turkey
Additional Information
Starting date: February 2011
Last updated: June 15, 2012
|